The Night Watch: Noven Pharma Climbs After Drug Trial Results

Investors were fairly active in the extended session Monday after the lowest volume day of the year in regular trading, but most stocks were staying close to their

4 p.m. closing levels.

Noven Pharmaceuticals

(NOVN) - Get Report

was a notable exception, rising 13% to $22.61. After the close, the company said its MethyPatch, a treatment for attention deficit hyperactivity disorder, was effective in a late-stage clinical trial. The company plans to file a new drug application with the Food and Drug Administration in the middle of the year.

SeeBeyond

(SBYN)

was going in the opposite direction, dropping 7.8% to $7.35 after the company said it expects to report first-quarter earnings, excluding items, of 3 cents a share on revenue of $42 million to $42.5 million. The earnings estimate is in line with analysts' consensus expectation, but the top line is shy of Wall Street's forecast of $44.5 million.

Volume was respectable on the Instinet platform. In the first 45 minutes of extended trading, more than 3.7 million shares changed hands among the top-20 volume movers.

Cisco

(CSCO) - Get Report

was the volume leader, slipping 0.2% to $17.48.

Broadcom

(BRCM)

was up 0.4% at $37.35.

WorldCom

(WCOM)

was inching up 0.1% to $6.90, and

Sun Micro

(SUNW) - Get Report

was ticking higher by 0.2% to $9.54.

Elsewhere,

Brocade

(BRCD)

was up 0.9%, the

Nasdaq 100 Unit Trust

(QQQ) - Get Report

was ahead by 0.1%, and

Dell

(DELL) - Get Report

was down 0.1%.

EMC

(EMC)

,

Microsoft

(MSFT) - Get Report

,

Oracle

(ORCL) - Get Report

and

Schwab

(SCH)

were active, but flat.